Trial Profile
A Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) Sourced From EU and US in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Eden Biologics; JHL Biotech
- 05 Jan 2020 Status changed from recruiting to completed.
- 04 Sep 2018 Planned End Date changed from 8 Sep 2018 to 31 Jan 2019.
- 04 Sep 2018 Planned primary completion date changed from 4 Aug 2018 to 15 Sep 2018.